OXiGENE to Present at Merriman Curhan Ford and Lazard Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical stage, biopharmaceutical company
developing novel therapeutics to treat cancer and eye diseases, announced today
that OXiGENE Management will present a corporate overview and update at the
Merriman Curhan Ford Investor Summit at 12:00 noon EST (9:00 a.m. PST) today at
the Sofitel Hotel in New York City, N.Y.

The Company will also present a corporate overview and update at the Lazard
Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17th, at
1:10 p.m. EST (10:10 a.m. PST), in the St. Regis Hotel in New York City, N.Y.

A live and archived webcast of each presentation can be accessed for 30 days
following the presentations by clicking on the Investors tab at www.oxigene.com.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases. The company's major focus is
developing vascular disrupting agents (VDAs) that selectively disrupt abnormal
blood vessels associated with solid tumor progression and visual impairment.
OXiGENE is dedicated to leveraging its intellectual property and therapeutic
development expertise to bring life-extending and life-enhancing medicines to
patients.

The OXiGENE, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4969

-0-
CONTACT: OXiGENE, Inc.
Investor and Media Contact:
Michelle Edwards, Investor Relations
650-635-7006
medwards@oxigene.com